- Home
- GMAB vs NXT Comparison
GMAB vs NXT Comparison
Compare GMAB & NXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMAB
- NXT
- Stock Information
- Founded
- GMAB 1999
- NXT 2013
- Country
- GMAB Denmark
- NXT United States
- Employees
- GMAB N/A
- NXT N/A
- Industry
- GMAB Biotechnology: Pharmaceutical Preparations
- NXT Semiconductors
- Sector
- GMAB Health Care
- NXT Technology
- Exchange
- GMAB Nasdaq
- NXT Nasdaq
- Market Cap
- GMAB 17.4B
- NXT 14.6B
- IPO Year
- GMAB N/A
- NXT 2023
- Fundamental
- Price
- GMAB $31.32
- NXT $90.40
- Analyst Decision
- GMAB Strong Buy
- NXT Buy
- Analyst Count
- GMAB 6
- NXT 21
- Target Price
- GMAB $40.40
- NXT $91.80
- AVG Volume (30 Days)
- GMAB 1.8M
- NXT 2.4M
- Earning Date
- GMAB 11-06-2025
- NXT 10-23-2025
- Dividend Yield
- GMAB N/A
- NXT N/A
- EPS Growth
- GMAB 132.41
- NXT N/A
- EPS
- GMAB 25.10
- NXT 3.85
- Revenue
- GMAB $3,845,670,022.00
- NXT $3,373,226,000.00
- Revenue This Year
- GMAB $24.92
- NXT $17.87
- Revenue Next Year
- GMAB $15.97
- NXT $12.64
- P/E Ratio
- GMAB $1.25
- NXT $23.37
- Revenue Growth
- GMAB 29.57
- NXT 20.37
- 52 Week Low
- GMAB $17.24
- NXT $33.29
- 52 Week High
- GMAB $33.65
- NXT $112.74
- Technical
- Relative Strength Index (RSI)
- GMAB 63.22
- NXT 48.05
- Support Level
- GMAB $29.98
- NXT $83.42
- Resistance Level
- GMAB $30.82
- NXT $93.43
- Average True Range (ATR)
- GMAB 0.65
- NXT 6.78
- MACD
- GMAB 0.15
- NXT -2.04
- Stochastic Oscillator
- GMAB 94.93
- NXT 24.78
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
About NXT Nextracker Inc.
Nextracker (and its subsidiaries) is a leading provider of intelligent, integrated solar tracker and software solutions used in utility-scale and distributed generation solar projects around the world. Nextracker's products enable solar panels in utility-scale power plants to follow the sun's movement across the sky and optimize plant performance. Nextracker has operations in the United States, Mexico, Spain and other countries in Europe, India, Australia, the Middle East, Africa, and Brazil.